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Abstract Improvements in early interventions after acute myocardial infarction (AMI), notably, the increased use of timely re-
perfusion therapy, have increased survival dramatically in recent decades. Despite this, maladaptive ventricular
remodelling and subsequent heart failure (HF) following AMI remain a significant clinical challenge, particularly be-
cause several pre-clinical strategies to attenuate remodelling have failed to translate into clinical practice.
Monocytes and macrophages, pleiotropic cells of the innate immune system, are integral in both the initial inflam-
matory response to injury and subsequent wound healing in many tissues, including the heart. However, maladap-
tive immune cell behaviour contributes to ventricular remodelling in mouse models, prompting experimental efforts
to modulate the immune response to prevent the development of HF. Seminal work in macrophage biology defined
macrophages as monocyte-derived cells that are comprised of two populations, pro-inflammatory M1 macrophages
and reparative M2 macrophages, and initial investigations into cardiac macrophage populations following AMI sug-
gested they aligned well to this model. However, more recent data, in the heart and other tissues, demonstrate re-
markable heterogeneity and plasticity in macrophage development, phenotype, and function. These recent insights
into macrophage biology may explain the failure of non-specific immunosuppressive strategies and offer novel op-
portunities for therapeutic targeting to prevent HF following AMI. Here, we summarize the traditional monocyte-
macrophage paradigm, experimental evidence for the significance of these cells in HF after AMI, and the potential
relevance of emerging evidence that refutes canonical models of monocyte and macrophage biology.
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1. Introduction
Emergency management of acute myocardial infarction (AMI) has been
revolutionized by timely reperfusion therapy and, in particular, increasing
access to primary percutaneous coronary intervention, leading to dra-
matic improvements in early survival.1–3 Despite this, AMI remains the
commonest cause of heart failure (HF) and HF-related morbidity and
mortality following AMI remain high.4–7 In view of the burden of HF fol-
lowing AMI, there is an unmet need for better understanding of the
pathogenesis of ventricular remodelling and development of novel thera-
peutic targets.
In AMI, reduced blood flow to a region of myocardium results in in-
farction, mediated mainly through oncosis and necrosis.8 This necrotic
myocardium becomes a region of mechanical weakness that requires
scar deposition to prevent myocardial rupture and limit functional dete-
rioration. This adaptive remodelling is necessary to prevent early mortal-
ity following AMI. However, excessive and progressive (maladaptive)
ventricular remodelling, at both the infarct site and remote myocardium,
Graphical Abstract
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..alters ventricular size and function, culminating in the clinical syndrome
of HF. Understanding the balance between adaptive and maladaptive
remodelling is an emerging research area that has the potential to iden-
tify novel therapeutic targets for the prevention of HF after myocardial
infarction (MI).
The innate immune response is an important regulator of this process
and comprises three key phases: the inflammatory, proliferative, and
maturation phases.8–10 Cell death triggers sterile inflammation, through
exposure of endogenous damage-associated molecular patterns
(DAMPs) to the innate immune system. Recognition of DAMPs by pat-
tern recognition receptors on resident innate immune cells prompts a
cascade of chemokine and pro-inflammatory cytokine release, recruiting
and activating neutrophils, monocytes, and macrophages. Together,
these cells degrade the extracellular matrix and phagocytose necrotic
cells. This initial inflammatory phase, which peaks around Day 3 post-in-
jury, is followed by a longer proliferative phase lasting around 10 days,
also mediated by immune cells. This phase is characterized by anti-
inflammatory signalling, fibroblast proliferation, and deposition of granu-
lation tissue. The final, maturation phase occurs over subsequent months
and is characterized by remodelling of the extracellular matrix, with few
immune cells present at the site of injury. During this period following
AMI, there are significant changes to ventricular size, shape, and function,
with maladaptive remodelling leading to the development of HF.11
Monocytes and macrophages are implicated at all three stages of this
response. Cardiac monocyte and macrophage numbers expand rapidly
in the days following AMI.12,13 These initial, infiltrating populations dem-
onstrate a pro-inflammatory phenotype which shifts over the ensuing
days to a predominantly reparative phenotype, coordinating the deposi-
tion of scar tissue.14 By 2 weeks post-AMI, monocyte and macrophage
populations at the site of infarction return to baseline, although macro-
phages persist for months after AMI in the remote, remodelling
myocardium.15
Nonetheless, numerous trials of immunosuppressive agents have
failed to mitigate HF following AMI, which is unsurprising given the com-
plex interplay of reparative and deleterious processes, and demonstrates
the need for a more detailed understanding of cellular and molecular
pathways in ventricular remodelling to facilitate more targeted therapeu-
tic interventions.16–18
The putative role of monocytes and macrophages in healing post-
AMI, and the persistence of macrophages in remodelling ventricular
myocardium, has led to interest in targeting these cells to prevent mal-
adaptive remodelling. However, various strategies to target specific sub-
populations have delivered seemingly contradictory results. This may re-
late to an overly constrictive traditional understanding and definitions of
macrophage subsets, which are increasingly understood to be heteroge-
neous and plastic, impeding focused investigation of their role in ventric-
ular remodelling after AMI.
Here, we discuss the canonical view of monocyte-derived macro-
phage differentiation and activation, and how strategies targeting mono-
cyte and macrophage populations have impacted on ventricular
remodelling in pre-clinical models. We then discuss emerging data on
the complexity of macrophage development and phenotype that chal-
lenges the existing paradigm and may justify disparities in existing evi-
dence. Finally, we discuss how recognition of macrophage heterogeneity
and plasticity may benefit ongoing investigation and the development of
new treatments in this important clinical area.
2. Traditional views of cardiac
monocyte and macrophage
populations
2.1 Monocyte and macrophage
classification
The mononuclear phagocyte system is a family of myeloid cells compris-
ing monocytes, macrophages, and dendritic cells. Monocytes are short-
lived circulating cells that are implicated in inflammation through both di-
rect effects and by differentiation into dendritic cells and macrophages.
These cells develop from the common myeloid progenitor in the bone
marrow and are released into the circulation, where they comprise two
main subsets: conventionally known as classical and non-classical. These
populations were originally described in humans, defined by CD16 (clus-
ter of differentiation 16) expression, and later in mice. Phenotypic profil-
ing suggests that these populations correspond, facilitating experimental
characterization of populations in human studies.19,20
Classical monocytes, typically described as CD14þCD16neg in humans
and Ly-6Chigh in mice, are implicated in inflammation.21,22 These cells are
released from the bone marrow and extramedullary sites of haemato-
poiesis, such as the spleen, and traffic to sites of injury in a CCR2 [che-
mokine (C-C motif) receptor 2] dependent manner, and comprise over
90% of circulating monocytes.22 Upon extravasation, classical monocytes
contribute to the innate immune response both via direct effects, such
as tumour necrosis factor a (TNF-a) and nitric oxide production, and in-
directly, by differentiation into macrophages and dendritic cells.23 More
recently, these cells have been shown to play an important role in acti-
vating the adaptive immune response, through antigen presentation to T
cells.23
In contrast, non-classical monocytes (CD14þCD16þ/Ly-6Clow) are
thought to persist in the circulation and their role in inflammation is less
clear. In mice, these cells have been demonstrated to arise in an NR4A1
(nuclear receptor subfamily four group A member one) dependent man-
ner, a transcription factor which is dispensable for classical monocyte de-
velopment.24,25 Both murine and human non-classical monocytes may
be differentiated from classical monocytes by high levels of CX3CR1 (C-
X3-C motif chemokine receptor 1) expression and, in mice, this recep-
tor has been demonstrated to be essential for their survival.22,26,27 These
cells patrol the endothelium and may play a role in immune
surveillance.28,29
On entry into tissues, monocytes give rise to dendritic cells and mac-
rophages. Macrophages phenotypically differ from monocytes by in-
creased expression of CD68 and MHCII (major histocompatibility 2), as
well as F4/80 in mice, and reduced expression of CD14 in humans.
Originally described as the prototypic phagocytic cells, macrophages are
now recognized to mediate incredibly diverse processes, from cytokine
production, phagocytosis, and co-ordination of the formation of granula-
tion tissue in the context of inflammation, to organ-specific homoeo-
static functions, the scope of which is still emerging in the heart.
Investigation of macrophage phenotype in vitro led to the widespread
use of the M1 and M2 polarization model to describe macrophages in
the context of inflammation.30 Macrophages stimulated with pro-
inflammatory signals, such as LPS (lipopolysaccharide) and IFN-c (inter-
feron-gamma), demonstrate a stereotypic pro-inflammatory transcrip-
tome and behaviour. These M1, or classically activated, macrophages
demonstrate enhanced phagocytosis, antigen presentation on MHC II,
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and generation of reactive oxygen species. They also produce and re-
lease pro-inflammatory cytokines, such as IL-12 (interleukin 12), IL-23,
IL-27, and TNF-a; chemokines, including CXCL9 (CXC motif chemokine
ligand 9), CXCL10, CXCL11; and matrix metalloproteinases (MMP-1, 2,
7, 9, 12). Together these contribute to a pro-inflammatory micro-
environment.
In contrast, macrophages stimulated with anti-inflammatory cytokines,
such as IL-4 and IL-13, show expression of characteristic anti-
inflammatory genes and a reparative phenotype.31 M2, or alternatively
activated, macrophages produce anti-inflammatory cytokines (IL-10);
chemokines, including CCL17 (C-C motif chemokine ligand 17),22,24 and
growth factors, such as vascular endothelial growth factor and tumour
growth factor beta. Together these mediators stimulate fibroblast-
mediated production of the extracellular matrix, cell proliferation and
angiogenesis, promoting tissue remodelling and repair.
Following these seminal studies, the M1–M2 activation paradigm con-
tinues to be widely used.
2.2 Cardiac monocyte and macrophage
populations in health and disease
During homoeostasis, both classical and non-classical monocytes are
found in the coronary vasculature. Intravital microscopy demonstrates
classical monocytes circulate rapidly, whereas non-classical monocytes
circulate more slowly, crawling along the endothelium.12,28,29 These pa-
trolling monocytes appear to play in role in immuno-surveillance. Within
the myocardium, macrophages are present in both the murine and hu-
man heart, comprising 6–8% of non-cardiomyocytes in the adult
mouse.32,33 These cardiac macrophages play a role in cardiac develop-
ment, immuno-surveillance and may contribute important specialized
cardiac functions, such as conduction, though their exact functional sig-
nificance is still emerging.10
Following AMI, monocyte and macrophage populations expand at the
site of infarction and change their phenotype dramatically in the murine
heart. Intravital microscopy demonstrates that monocyte recruitment to
the infarct begins as early as 30 min following AMI, first from the vascular
pool and later from the splenic reservoir.12 This initial recruitment is rap-
idly overtaken by neutrophil infiltration, and recent evidence suggests
these sentinel infiltrating monocytes may play a role in neutrophil
attraction.34
The infiltration of monocyte and macrophage populations into in-
farcted tissue occurs in two sequential phases.13,14 Ly-6Chigh monocytes
are the predominant population early post-AMI, peaking between Days
3 and 5, and demonstrating a pro-inflammatory phenotype, including
TNFa expression and high proteinase activity. Ly-6Chigh macrophages
form the principal macrophage subset during this early phase, though
they are less abundant than monocytes.35As inflammation resolves, Ly-
6Clow cells predominate, peaking in the infarct on Day 7 post-AMI.14
Initially described as a distinct wave of Ly-6Clow monocyte infiltration,
more refined gating strategies and lineage tracing experiments have dem-
onstrated these cells to be principally Ly-6Clow macrophages, which are
derived from Ly-6Chigh monocytes.35
A similar pattern of sequential Ly-6Chigh and Ly-6Clow expansion is
observed in the remote myocardium.13 However, Ly-6Clow numbers
peak 5 days later than at the infarct site. Importantly, in contrast to the
site of ischaemia, macrophages and Ly-6Chigh monocytes persist in the
non-ischaemic myocardium (Figure 1).15
These changes in monocyte and macrophage populations in the myo-
cardium following AMI are accompanied by an expansion of circulating
monocytes.14,36 The major source of circulating monocytes following
AMI is the splenic reservoir, and these cells are generated both by seed-
ing from the bone marrow and by local monocytopoiesis.36–38 The
spleen contains myeloid precursors that expand rapidly after AMI; on
adoptive transfer of splenic granulocyte-macrophage progenitors after
AMI, these cells differentiate into splenic macrophages that mobilize to
the healing myocardium.38 Monocytopoiesis at both medullary and
extramedullary sites is regulated by sympathetic nervous signalling and
IL-1, both in the acute and chronic phase following AMI.15,38,39
Human studies of cardiac populations following AMI demonstrate a
similar pattern of infiltration to that observed in mice. Humans demon-
strate peripheral blood monocytosis after AMI, with sequential peaks of
CD14þCD16neg and CD14þCD16þ monocytes on Days 3 and 5, re-
spectively, though CD14þCD16neg monocytes are more abundant
throughout.40 This was confirmed in an analysis of post-mortem cardiac
tissue, which showed a predominance of CD16- cells during the inflam-
matory phase, compared to comparable populations of CD16þ and
CD16- cells during the proliferative phase.41 Both the bone marrow and
splenic reservoir of monocytes (defined as CD14þ cells) were signifi-
cantly depleted in this study.
3. Monocyte–macrophage phenotype
and ventricular remodelling
3.1 Pro-inflammatory phenotypes corre-
late with ventricular dysfunction in mice
and humans
The role of monocytes and macrophages in wound healing and the ob-
servation of two distinct waves of infiltration after AMI has led to the hy-
pothesis that these cells may have a role in maladaptive ventricular
remodelling and the development of HF. Observational studies in mice
and humans demonstrate a correlation between classical monocytosis
and degree of LV dysfunction after AMI. For example, the ApoEneg/neg
(Apoprotein E) model demonstrates a chronically expanded pool of cir-
culating Ly-6Chigh monocytes.42 Following coronary artery ligation, these
mice show increased myocardial infiltration and persistence of Ly-6Chigh
monocytes on Day 5 and reduced left ventricular ejection fraction
(LVEF) at 3 weeks, compared to wild-type mice. Similarly, in patients fol-
lowing ST-segment elevation MI (STEMI), there is a negative correlation
between peripheral blood monocytosis and recovery of ventricular func-
tion.43 In one study, peak circulating CD14þCD16neg levels following
STEMI negatively correlated both with wound healing (assessed by the
extent of myocardial salvage on cardiac magnetic resonance imaging at
Day 7) and LVEF at 6 months, though the degree of HF at follow-up is
likely to have been confounded by the greater initial infarct size.40
These findings have been corroborated when classical monocytes are
defined as CD14þCD62Lþ cells, with high levels associated with greater
infarct size and regional systolic LV dysfunction at 4-month follow-up af-
ter STEMI, which remained significant even after stratification according
to the extent of transmural infarction.44 An inverse trend was observed
with the number of non-classical monocytes (CD14þCD62Lneg), with
high levels correlating to improved LV function, though this was not sta-
tistically significant. However, crucially, these patients were taken from
the HEBE trial, where subjects received intracoronary infusions of autol-
ogous peripheral blood mononuclear cells (PBMC) following AMI. Given
the expansion of circulating classical monocyte populations following
AMI, the outcomes at later time points are likely to be confounded by
4 C. Peet et al.
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the intracoronary infusion of these pro-inflammatory skewed PBMC
populations. The trial itself failed to show a significant effect of intracoro-
nary infusion of autologous PBMC on left ventricular size or function at
4-month follow-up and, interestingly, revealed increased mortality and a
reduction in recovery of left ventricular function at 24 months when
compared with control.45,46
3.2 Targeting circulating monocytes and
their reservoirs
To better understand, the specific contributions of monocyte and
macrophage subsets on remodelling following AMI, studies have fo-
cused on either blocking monocyte recruitment to the myocardium
or manipulating the phenotype of myocardial monocytes and macro-
phages (Figure 2).
The correlation of monocytosis with poor outcomes led to the hy-
pothesis that excessive monocyte infiltration is deleterious. However,
treatment with clodronate-loaded liposomes after AMI, which deplete
circulating monocytes (Figure 2A), either during the early pro-
inflammatory phase or later proliferative phase, leads to impaired infarct
repair.14 In both instances, reduced collagen deposition and angiogenesis
are seen during the proliferative phase, whilst only depletion of early
monocytes increases necrotic cells and debris, suggesting that both the
pro-inflammatory early phase and later reparative phase are essential for
infarct healing.
A number of studies have, therefore, sought to selectively target traf-
ficking of Ly-6Chigh monocytes to the myocardium, taking advantage of
the observation that Ly-6Clow monocytes traffic independently of CCR2
(Figure 2B). Following coronary artery ligation, Ccr2neg/neg mice demon-
strate reduced myocardial infiltration of Ly-6Chigh cells and siRNA
knockdown of Ccr2 in wild-type mice reduces Ly-6Chigh monocyte infil-
tration of the myocardium and improves LVEF and left ventricular end-
diastolic volume (LVEDV) in these mice.14,47 Notably, CCR2 is not only
Figure 1 Myocardial monocyte and macrophage populations after AMI. (A) Infarct site inflammatory cell populations expand rapidly following AMI with
an initial expansion of Ly-6Chigh monocytes, peaking Day 3–5, followed by an expansion of Ly-6Clow macrophages, peaking on Day 7. (B) By 6 weeks, inflam-
matory cell infiltration at the infarct site has returned to baseline, leaving an acellular collagen based scar, whereas Ly-6Clow macrophages persist in the re-
mote, remodelling myocardium.
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important for attraction of Ly-6Chigh monocytes to the myocardium but
is also necessary for their mobilization from the bone marrow, and
therefore, these models are likely to be exerting some of their effect via
bone marrow mobilization and, in the case of constitutive knockout,
prior seeding of the spleen by monocytes that originated in the bone
marrow (Figure 2C).48
However, while targeting CCR2 can impede Ly-6Chigh monocyte traf-
ficking, release of monocytes from the spleen occurs independently of
CCR2 and splenic monocytes have been demonstrated to contribute to
maladaptive ventricular remodelling (Figure 2D).36 Splenectomy in mice
8 weeks post-coronary artery ligation appears to improve ventricular
function, as assessed by LVEDV and LVEF, whilst control mice that re-
ceived sham abdominal surgery demonstrated ongoing deterioration of
LV function.37 Similarly, adoptive transfer of splenic monocytes from
mice with ventricular dysfunction post-AMI caused maladaptive ventricu-
lar remodelling in the recipients. In contrast, adoptive transfer of LPS-
stimulated splenic monocytes did not induce ventricular remodelling,
suggesting alterations specific to the splenic niche in the context of HF
modulate monocyte phenotype, and that this phenotype is functionally
distinct from that of in vitro derived pro-inflammatory monocytes.
Interestingly, release of splenic monocytes has been shown to depend
on the angiotensin II Type 1a receptor, and knockout of this receptor
reduces both circulating and myocardial monocytes following AMI.36 It is
possible that the effect of drugs that inhibit the renin–angiotensin system,
which are in routine use in the prevention and treatment of HF following
AMI, is partially mediated via this mechanism.
A final target to deplete myocardial monocyte populations is monocy-
topoiesis (Figure 2E). Targeting IL-1b, a cytokine that promotes monocy-
topoiesis following AMI, reduces circulating monocyte levels following
coronary artery ligation and mitigated deterioration of LV function at
3 weeks.49 These findings are pertinent in light of the recent success of
the monoclonal antibody to IL-1b, canakinumab, in prevention of cardio-
vascular events in patients with previous AMI.50 Sympathetic nervous
system signalling has been demonstrated to drive monocytopoiesis and
the routine use of b adrenergic blockade as cardio-protection following
AMI may be exerting some effect via this mechanism.15 The impact on
myocardial monocyte infiltration after AMI of inhibitors of both the re-
nin–angiotensin system, implicated in splenocyte release, and the b adre-
nergic system, implicated in monocytopoiesis, remains to be
characterized. Without such characterization, efforts to translate puta-
tive strategies targeting these cells may be confounded by the unknown
impact of these commonly prescribed medications.
Other studies have hypothesized that Ly-6Clow monocytes may pro-
tect against ventricular remodelling by attenuating inflammation. Mice
deficient for Nr4a1, an obligate transcription factor for Ly-6Clow mono-
cyte development, showed absent circulating and myocardial Ly-6Clow
monocytes and impaired LV function, with reduced LVEF and increased
LVEDV at 21 days post-coronary artery ligation, compared to wild-type
mice.35 However, rather than mediating its effects solely through deple-
tion of Ly-6Clow monocytes, the authors demonstrated that Nr4a1 dele-
tion also modulated the behaviours of Ly-6Chigh monocytes and both
macrophage subsets. In particular, Ly-6Chigh monocytes demonstrated
increased expression of CCR2 and infiltration of the infarct site was in-
creased. Absolute numbers of Ly-6Chigh and Ly-6Clow macrophages
were increased in the myocardium on Day 7, and global macrophage
transcription was skewed towards a pro-inflammatory phenotype, with
increased expression of IL-1ba, TNFa, and IL-6, and reduced expression
of canonical M2 marker, CD206.
3.3 Targeting myocardial macrophage
phenotype
NR4A1 is one of a number of identified molecular targets that links mac-
rophage phenotype with ventricular remodelling. Initial studies showed
that up-regulating canonical M2 genes in myocardial macrophage popula-
tions, using IL-4 or IL-10 treatment or GABAAR (gamma aminobutyric
acid A receptor) agonism, following coronary artery ligation protects
against ventricular remodelling.51–53 However, these approaches are
non-specific as they also manipulate other cell types, including T-reg
cells, and fail to demonstrate a causal role for macrophages or any partic-
ular subset.
Specific targeting of macrophage polarization, therefore, provides
more convincing evidence of a causative role for macrophages in both
early infarct repair and ventricular remodelling. Knockout of Trib1
(Tribbles pseudokinase 1) causes a selective depletion of CD206þ mac-
rophages, a population described in this study as M2 macrophages.53
Following coronary artery ligation, Trib1 deficient mice demonstrate a
nine-fold increase in cardiac rupture, and this phenotype is salvaged by
adoptive transfer of CD206þ macrophages, providing evidence of a ben-
eficial role for reparative macrophages early in the inflammatory phase.
Trib1neg/neg demonstrated impaired LV function compared to wild type,
implicating this macrophage population in protecting against ventricular
remodelling. Similarly, in an Mmp28 knockout model, which shows
Figure 2 Targeting circulating monocytes and their reservoirs.
Approaches depleting myocardial monocyte populations following AMI
have focused on various stages of their trafficking upstream. (A)
Depletion of all circulating monocytes (e.g. clodronate-loaded lipo-
somes). (B) Inhibition of monocyte entry into the myocardium (e.g.
Ccr2neg/neg). (C) Inhibition of monocyte release from the bone marrow
(e.g. Ccr2neg/neg). (D) Depletion of the splenic reservoir or inhibition of
splenic release (e.g. splenectomy, Agt1ar antagonism). (E) Inhibition of
monocytopoiesis (e.g. beta-adrenergic blockade).
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reduced capacity of peritoneal macrophages to differentiate into M2
macrophages in vitro, ventricular function was impaired at 7 days com-
pared to wild types after coronary artery ligation.54 Cardiac macrophage
numbers were not significantly altered, but expression of canonical M1
markers was increased and M2 markers were reduced.
Efferocytosis, the phagocytosis of apoptotic cells, has been hypothe-
sized as a cell-intrinsic mechanism by which macrophages might shift
from a pro-inflammatory to reparative phenotype. Constitutive knock-
out of Mertk (Mer tyrosine protein kinase), a receptor tyrosine kinase re-
quired for effective efferocytosis, led to increased expression of
canonical M1 genes in macrophages and exacerbated deterioration in LV
function after coronary artery ligation.55
Conversely, blocking pathways implicated in M1 macrophage polariza-
tion was hypothesized to protect cardiac function after coronary artery
ligation. siRNA targeting of Irf5 (interferon regulatory factor 5), a tran-
scription factor implicated in M1 polarization, resulted in reduced ex-
pression of the canonical M1 markers TNF-a and IL-1b, but no change in
M2 marker expression on Day 4 post-coronary artery ligation.56 These
mice had similar infarct sizes but knockdown reduced LV dilatation at
3 weeks.
These observations led to the hypothesis that shifting the macrophage
phenotype from the pro-inflammatory M1-like macrophage to an anti-
inflammatory M2-like macrophage protects the heart from adverse
remodelling following AMI. However, more recent evidence has chal-
lenged the use of the M1–M2 paradigm by demonstrating improved out-
comes following knockout of Gata3 (GATA-binding factor-3), a
transcription factor implicated in the differentiation of M2 macro-
phages.57 Selective knockout of Gata3 in myeloid cells depleted Ly-6Clow
but not Ly-6Chigh macrophages following AMI and, surprisingly, the Ly-
6Clow macrophage depleted mice demonstrated improved LV size and
function at 2 months post-AMI. Additionally, absolute numbers of Ly-
6Chigh macrophages increased in the knockout model, challenging the
view that the presence of excessive early pro-inflammatory populations
is deleterious.
To reconcile this study with the view that M2 macrophages are pro-
tective requires careful re-examination of the canonical M1–M2 macro-
phage model. The variety and limitations of methods to define
macrophage populations means that cell populations described in vari-
ous studies may not necessarily align to one another. Emerging analyses
of the wide phenotypic spectrum of macrophages, as well as the exis-
tence of non-monocyte-derived macrophage subsets, supports this
view.
4. Insights into the complexity of
mononuclear cell populations
following AMI
4.1 Macrophages in vitro and in vivo exhibit
a network of stimulus-dependent
phenotypes
The M1–M2 paradigm is based on the polarization of bone marrow-de-
rived macrophages in response to LPS and IFN-c or IL-4 and IL-13.30
However, when human macrophages are stimulated in vitro with a more
diverse range of cytokines than originally described, many more distinct
phenotypes result, with one study eliciting 299 distinct transcriptomes
that do not map along a spectrum from M1 to M2.58 Similarly, the co-
expression of canonical M1 and M2 markers in both mouse and human
macrophages is well characterized, as is the ability of M1 or M2 macro-
phages to acquire canonical markers of the other subset in vitro.59,60
Accordingly, the M1–M2 paradigm is widely accepted as an over-
simplification, and yet it continues to guide experimental study design
in vivo.61
With this in mind, studies targeting particular transcriptional pathways
are likely to be affecting only a subpopulation of M1 or M2 cells. For ex-
ample, knockout of Gata3 depletes CCR2negLy-6Clow macrophages but
does not eliminate them, suggesting that only a proportion of these cells
are Gata3-dependent (Figure 3A). It is, therefore, misleading to conclude
that M2 macrophages are responsible for the observed experimental
phenotype. This also demonstrates the limitations in current definitions
of macrophage subsets, as markers used to describe M1 and M2 popula-
tions vary between studies, and accordingly, the populations described
are not comparable.
Novel techniques that allow resolution of gene expression at the sin-
gle-cell level, including single-cell RNA sequencing (scRNA-seq) and
mass cytometry, may help overcome these issues (Figure 3B). scRNA-
seq assesses the transcriptome at single-cell level and enables unbiased
clustering of cells based on common expression profiles. scRNA-seq of
murine aortic macrophages defined three clusters of macrophages: ‘Res-
like’, which were present in healthy and atherosclerotic aortas, as well as
inflammatory and Trem2high (triggering receptor expressed on myeloid
cells 2) macrophages, which were only present in atherosclerosis.62
Whilst inflammatory and Res-like macrophages overlapped significantly
with the transcriptomes of in vitro-derived M1 and M2 macrophages, re-
spectively, inflammatory macrophages were enriched for Nrf2 (nuclear
factor erythroid2 related factor 2), an anti-inflammatory transcription
factor, and Mrc1 (mannose receptor C Type 1), which encodes CD206,
a cell surface marker often used to define M2 macrophages. The newly
described Trem2high subset did not align to either the M1 or M2 profile.
Interestingly, in contrast to the diversity of macrophage populations,
application of scRNA-seq to circulating monocytes in mice suggests that
these cells do align well to the classical and non-classical monocyte para-
digm.63 Ly-6Chigh and Ly-6Clow cells have distinct and well-conserved
transcriptomes. The authors of this particular study also address the
transcriptional networks of a third population of monocytes. This third
population, defined by intermediate expression of Ly-6C in mice and
CD16 in humans, has long been recognized and is hypothesized to rep-
resent an intermediate developmental stage. The authors demonstrated
heterogeneity in the transcriptional profiles of these Ly-6Cint cells, and
argued that this lent further support to the hypothesis that these cells
represent an intermediate developmental stage between classical and
non-classical monocytes.
The resolution of scRNA-seq in distinguishing monocyte and macro-
phage populations is limited by significant overlap in transcriptional pro-
files between clusters, given their common lineage. Mass cytometry
addresses this issue by using a large panel of heavy metal-conjugated anti-
bodies targeting known or suspected differentially expressed proteins.64
Application of mass cytometry to the analysis of aortic macrophages de-
scribed above was able to further subdivide phenotypes that had already
been defined by scRNA-seq.65 This method of immunophenotyping
allows simultaneous analysis of up to 40 proteins and more specific reso-
lution of subsets compared to traditional flow cytometry. Comparison
of populations defined using mass and flow cytometry has demonstrated
a tendency to misclassify monocytes and macrophages and may account
for some of the observed inter-study variation.14,35,66 Given the complex
networks regulating gene expression at the translational and post-
translational level, the combination of strategies to interrogate both
Monocytes and macrophages after MI 7
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RNA expression and protein expression is important to appreciate the
relevant effector pathways in these cells.
Whilst mass cytometry is, to our knowledge, yet to be applied to car-
diac macrophages, emerging data from scRNA-seq and novel experi-
mental models of AMI illustrate macrophage diversity during
homoeostasis and following AMI, novel mechanisms by which macro-
phage populations develop following AMI, and potential mechanism by
which they modulate ventricular remodelling.
4.2 Cardiac mononuclear cells
demonstrate diverse gene expression
during homoeostasis
Tissue resident macrophages (TRM) are present in the myocardium dur-
ing homoeostasis, comprising 7–8% of non-cardiomyocytes in the steady
state.32 Initial fate mapping experiments in mice divided these cells
according to CCR2 expression, demonstrating that CCR2þ cells are de-
rived from and dependent on circulating CCR2þ monocytes, whereas
CCR2neg macrophages are of mixed ontogeny, arising both from the em-
bryonic yolk sac and from foetal liver haematopoietic stem cells. 67 This
is in contrast to other organs, such as the brain, where TRM are entirely
independent of circulating monocytes. These findings have been recapit-
ulated in human hearts, where CCR2neg tissue resident populations have
also been demonstrated to be maintained through proliferation, inde-
pendent of circulating monocytes, whilst CCR2þ macrophages depend
on circulating CCR2þmonocyte recruitment and proliferation.68
Use of scRNA-seq has demonstrated greater heterogeneity of myo-
cardial TRMs than previously appreciated, identifying 11 clusters of
mononuclear phagocytes with distinct gene expression profiles, com-
prising one monocyte cluster, four macrophage clusters, three dendritic
cells clusters, one myeloid antigen presenting cell cluster, and two clus-
ters of proliferating cells.69 Pathway analysis of these subsets suggests dif-
fering functions during homoeostasis. The first cluster is enriched for
genes involved in reparative functions, such as efferocytosis and angio-
genesis, including Timd4 (T-cell immunoglobulin and mucin containing
domain-4), Lyve1 (lymphatic vessel endothelial hyaluronan receptor 1),
and Igf1 (insulin-like growth factor 1). These cells are entirely maintained
through local proliferation, and likely form a subset of the CCR2neg cells
described before. A second cluster was unique in its expression of Ccr2,
and was found to be enriched for genes involved in cell migration,
Figure 3 Advantages of high throughput techniques to examine immune cell heterogeneity. (A) Flow cytometry is widely used to immunophenotype
monocytes and macrophages. A common gating strategy in mice defines these cells as CD45þCD11bþLy-6Glow. Based on Ly-6C and F4/80 expression
these cells are commonly described as classical (Ly-6ChighF4/80low) and non-classical monocytes (Ly-6ClowF4/80low), and M1 ((Ly-6ChighF4/80high) and M2
(Ly-6ClowF4/80high). Cells expressing a particular transcription factor, termed X, may not align well with the M1/M2 paradigm, Knockout of this transcription
factor may preferentially deplete a particular population, such as M2 macrophages, but is neither sensitive nor specific, failing to deplete all ‘M2’ macrophages,
and also depleting cells of other subsets. (B) Novel high throughput techniques allow unbiased resolution of cells into distinct populations, based on gene ex-
pression profile (scRNA-seq) or large panels of differentially expressed proteins (mass cytometry). Such methods allow identification of candidate pathways
for therapeutic targeting and ensure knockout models selectively deplete the population of interest. DC, dendritic cells; Mo, monocytes; M/, macrophages;
N/, neutrophils.
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hypoxic response, and the respiratory burst, suggesting a pro-
inflammatory role. As previously described, these cells were entirely
replaced by differentiation of circulating monocytes. The final popula-
tions were of mixed lineage, maintained both by local proliferation and
by differentiation of circulating monocytes, and were characterized by
enrichment of genes involved in antigen presentation and interferon-
stimulated genes, respectively. This study demonstrates the utility of high
throughput techniques in both resolving populations that are otherwise
described homogenously and identifying novel target pathways.
In addition to these myocardial macrophages, the pericardial cavity, a
serous cavity surrounding the heart, has long been known to contain
macrophages.70,71 Whilst high throughput methods are yet to be applied
to these macrophages, immunophenotyping by flow cytometry groups
three distinct myeloid clusters, MHC IIþ macrophages, GATA6þ macro-
phages, and dendritic cells, during homoeostasis.72 Bulk RNA-seq dem-
onstrates that the transcriptional profile of GATA6þ pericardial cavity
macrophages is more similar to that of other serous cavity macrophages,
namely pleural and peritoneal, than to cardiac TRM, suggesting con-
served functions for serous cavity macrophages across different organ
systems. Pericardial macrophages were enriched for genes associated
with homoeostasis and metabolism, whilst cardiac TRM were relatively
enriched for genes involves in inflammation and, whilst this study did not
take into account the newly recognized heterogeneity of cardiac TRM, it
does illustrate the existence of a distinct populations of macrophages,
whose contributions to cardiac homoeostasis and following injury has
hitherto not been appreciated.
4.3 The heterogeneity and plasticity of
macrophage transcriptomes following AMI
Comparison of macrophage populations before and after AMI offers
insights into the mechanisms of macrophage differentiation and suggests
candidate therapeutic targets to mitigate ventricular remodelling.
scRNA-seq of mononuclear phagocytes in the infarcted myocardium
11 days after coronary artery ligation showed preservation of the four
macrophage clusters described during homoeostasis, in addition to four
novel macrophage populations.69 Pathways enriched in the AMI specific
populations were involved in the inflammatory response, including TNF
production, cell migration and adhesion, and hypoxic signalling.
Analysis of the preserved homoeostatic populations between non-in-
farcted and infarcted tissue, showed near identical gene expression, with
the exception of a number of core TRM genes, including Timd4, Lyve1,
and Igf1, which play important roles in angiogenesis and efferocytosis.69
It is well-established that TRM in the infarct zone undergo rapid cell
death following AMI and that macrophages at the infarct site are derived
from a rapid influx of circulating monocytes.32,38 These data, therefore,
illustrate both the remarkable plasticity of circulating monocytes to dif-
ferentiate into diverse macrophage populations, as well as a core signa-
ture of TRM genes involved in reparative functions that are lost
following AMI and that may represent novel therapeutic targets.
Whilst TRM are depleted in the infarct zone following AMI, emerging
data suggest these cells play critical roles in remodelling following AMI.73
Global depletion of TRM, by transient inducible knockout of Cx3cr1,
results in increased recruitment of monocytes and macrophages to the
remote myocardium and greater ventricular remodelling, with reduced
LVEF, increased fibrosis and excess mortality 35 days following coronary
artery ligation.69 However, selective depletion of Ccr2þ TRM results in
reduced monocyte recruitment to the infarcted myocardium and im-
proved ventricular size and function compared to wild types 28 days af-
ter an ischaemia–reperfusion (I/R) model of AMI, whilst selective
depletion of CD169þ TRM resulted in worse ventricular outcomes, with
reduced ejection fraction and end-diastolic volume, suggesting both criti-
cal and subset-specific roles for TRM populations in ventricular remodel-
ling post-AMI.
To understand how TRM may be acting, it is important to consider
the roles of macrophages in different regions of the myocardium follow-
ing injury (Figure 4). Whilst TRM are rapidly depleted in the ischaemic
zones following AMI, there is rapid expansion of Lyve1neg TRM specifi-
cally in the peri-infarct zone from Day 2 post-coronary artery ligation.69
Most studies investigating macrophages after AMI do not differentiate
between regions (infarct, peri-infarct, and remote) of the myocardium,
and those that do rarely investigate the peri-infarct or remote myocar-
dium specifically, focusing instead on the infarct zone. In the remote
myocardium, absolute numbers of macrophages in the remote myocar-
dium expand and persist in the remote myocardium 8 weeks following
AMI, and recent analyses suggests it is increased monocyte recruitment
and differentiation, rather than TRM expansion, that accounts for
this.15,69 Recognizing that macrophage populations may have different
roles depending on their location following AMI is an important concep-
tual shift that may facilitate greater understanding of the mechanisms by
which they contribute to ventricular remodelling.
Figure 4 Novel macrophage populations appear to play spatially re-
stricted roles in remodelling of the myocardium following AMI.
Following AMI, at the infarct site, TRM undergo rapid cell death, and
monocytes rapidly extravasate and differentiate into macrophages. In
contrast, in the peri-infarct zone a subpopulation of TRM persist and
rapidly proliferate following AMI, whilst monocyte-derived macro-
phages also contribute to rapid expansion of macrophage numbers at
this site. Finally, in the remote myocardium, TRM persist but do not ap-
pear to contribute to the increased absolute numbers of macrophages,
which is due to infiltration of circulating monocytes. A final, pericardial
macrophage population has been identified following AMI. These cells
do invade the myocardium but also attach to the epicardial surface and
may mediate ventricular remodelling via paracrine signalling.
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In addition to spatially restricted roles, there appears to be significant
temporal variation in macrophage phenotype following AMI. Whilst
scRNA-seq is yet to be applied to investigate temporal variation follow-
ing AMI, bulk RNA-seq of cardiac macrophages illustrates a temporal
shift in macrophage phenotype from pro-inflammatory to reparative to
resident like.74,75 Whilst macrophages on Day 3 and Day 7 demon-
strated predominantly pro-inflammatory and reparative gene expression
profiles respectively, both populations showed mixed expression of ca-
nonical M1 and M2 genes, again supporting a more nuanced approach to
description of M1-M2 phenotypes.75
Combination of scRNA-seq to identify candidate pathways and use of
transient inhibitors offers a strategy to delineate temporally defined
pathogenic pathways. For example, analysis of single-cell transcripts in
cardiac macrophages on Day 4 following coronary artery ligation dem-
onstrated the presence of an interferon inducible cell cluster, that was
absent in Irf3neg/neg mice.76 Such a cluster has also been identified during
homoeostasis and following I/R injury, and, crucially, is distinct to the
CCR2þ cluster, two populations that previously may have been de-
scribed synonymously as M1 macrophages.69 To investigate the func-
tional relevance of one such novel population, the investigators targeted
one candidate pathway. Macrophages of this cluster were enriched for
components of the IRF3-IFN (interferon regulatory transcription factor
3–interferon) pathway, which detects cytosolic DNA and initiates an in-
terferon response. Deletion, using constitutive knockout models, of vari-
ous components of the pathway protected against ventricular
remodelling following coronary artery ligation. Crucially, of potential
translational application, administration of IFNAR (interferon alpha re-
ceptor) neutralising antibody at 12 and 48 h post-AMI abrogated down-
stream gene expression, improved ventricular size, contractile function,
and mouse survival.
The use of a technique to transiently block pathways allows better
resolution of the role of particular macrophage phenotypes at different
time points following AMI. For example, one might hypothesize that a
pathway involved in stimulating fibroblast activity may be beneficial early
following AMI but contribute to remodelling if persistently active days to
weeks later. Constitutive knockouts are unable to delineate the relative
significance of these pathways, whereas techniques to transiently target a
pathway would offer translational potential by testing candidate thera-
pies and demonstrating the ideal time points for intervention.
4.4 The impact of model systems on
macrophage phenotype
The impact of both timing and location on macrophage phenotype sug-
gests significant interplay between the microenvironment and macro-
phage plasticity. Permanent coronary artery ligation is widely used to
model AMI because it causes significant necrosis and a reproducible in-
flammatory response. However, in the era of widespread clinical access
to reperfusion therapy, important differences between permanent and
transient coronary artery ligation models should be considered, including
the infarct burden and contribution of reperfusion injury. For example,
macrophage populations after I/R have a temporally shifted immune re-
sponse, with macrophage populations at the infarct site peaking 4 days
earlier than in the permanent ligation model and having almost
completely resolved by 7 days.77 The study did not address changes in
monocyte or macrophage phenotype, but this is an important outstand-
ing research question. Without confirming the impact of therapeutic tar-
gets on ventricular remodelling using an I/R model, candidate studies risk
identifying genes and pathways that are of limited translational relevance.
Moreover, recent insights into the role of serous cavity macrophages
following visceral injury suggests a fundamental limitation of conventional
coronary artery ligation and I/R models, as they require disruption of the
parietal pericardium to access the coronary arteries and therefore may
interfere with the response of pericardial macrophages to cardiac injury.
GATA6þ serous cavity macrophages are found in the pericardial, pleural
and peritoneal cavities during homoeostasis, and their function following
injury is best characterized in the peritoneum, an analogous anatomical
structure of the abdomen.78,79 These cells are rapidly recruited to the
site of acute liver injury, via a non-vascular route that significantly outpa-
ces extravasation of monocytes and contributes to tissue repair through
disassembly of necrotic nuclei and promotion of angiogenesis.80
Modelling MI using a modified coronary artery ligation model, that leaves
the parietal pericardium intact, produces a similar infarct size to conven-
tional coronary artery ligation models but, crucially, mice with an intact
pericardium show relatively preserved LV function at 4 weeks, suggesting
a role for the pericardium in protecting against ischaemic remodelling.72
This cardio-protective effect of the pericardium was abrogated in mice
lacking Gata6þ pericardial macrophages. Specifically, mice lacking Gata6þ
macrophages showed increased fibrosis of the remote myocardium, im-
paired LV function and increased LV stiffness at 4 weeks following AMI,
modelled using modified coronary artery ligation, despite similar initial in-
farct sizes, compared to wild-type controls. These cells do migrate into
the myocardium but are localized predominantly around the epicardial
surface, leading authors to postulate a possible paracrine mechanism of
action. Accordingly, future strategies targeting macrophages may need
to address not only cells present in the myocardium but also cells at-
tached to the epicardial surface or in the pericardial space, which may
contribute to modulation of remodelling via paracrine mechanisms.
5. Conclusions and future directions
Given the growing body of evidence demonstrating wide phenotypic
variation of macrophages in vivo following AMI, understanding their con-
tribution to pathological remodelling requires evolution from the estab-
lished M1-M2 paradigm. This model assumes a continuum from M1 to
M2, whereas in vivo evidence suggests a network of diverse macrophage
behaviours, driven by a complex network of stimuli.
Interpretation of studies investigating monocyte and macrophage
populations is limited by poor phenotypic resolution, and this may ac-
count for apparent inconsistencies in the literature. The emergence of
unbiased, high throughput single-cell techniques will facilitate more spe-
cific identification of candidate macrophage populations and novel signal-
ling pathways for therapeutic application. Furthermore, accounting for
temporal and spatial variation will further contribute to our understand-
ing of the regulation of monocyte and macrophage phenotype. These
novel techniques will need to be complemented by mechanistic studies
to demonstrate the functional significance of newly described
phenotypes.
Despite compelling evidence for a key role for monocytes and macro-
phages in ventricular remodelling following AMI, targeted immunothera-
peutic strategies are slow to emerge. Insights into macrophage biology in
the context of atherosclerosis led to the first successful clinical trial of
immunotherapy in cardiovascular disease (CANTOS) and this success
provides a proof of concept for the utility of immunotherapy in this field.
In light of the heterogeneity and plasticity of monocytes and macro-
phages in the heart following AMI, a conceptual shift from targeting arbi-
trarily and inconsistently defined myeloid cell populations to targeting
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candidate pathways identified in these cells may bridge the current gap
between our current knowledge and therapeutic strategies.
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